SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network
Main finding · Composite outcomeResult — go to the resultHazard ratio 0.61 95% CI 0.38–0.97Authors' conclusion
In a large real-world FD cohort, SGLT2i exposure was associated with lower cardiovascular risk and mortality
Study context
- Population
- Adults with Fabry disease and eGFR ≥ 20 mL/min/1.73 m², excluding T1D; TriNetX Global Collaborative Network732 per group after PSM
- Participants
- 14,940 adults
- Exposure
- SGLT2i exposure vs no exposure
- Exposedn = 732
- Non-exposedn = 732reference
- Outcome
- Composite of:
- All-cause death
- Acute MI and acute or acute-on-chronic HF
- Follow-up
- 2 and 5 years
Methodological detailspropensity-score matched (1:1), federated research network (TriNetX Global Collaborative Network)
- Propensity-score matched (1:1)
- Federated research network (TriNetX Global Collaborative Network)
Main finding
Composite outcome · 2 years
Hazard ratio
0.61
95% CI 0.38–0.97
Exposedvs Non-exposed
HR 0.61 (95% CI 0.38–0.97)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
All-cause death · 2 years
- SGLT2i exposure vs non-exposure, HR
- 0.56 (95% CI 0.33-0.95)
- Propensity-score matched
All-cause death · 5 years
- SGLT2i exposure vs non-exposure, HR
- 0.62 (95% CI 0.42-0.93)
- Propensity-score matched
Myocardial infarction · 5 years
- SGLT2i exposure vs non-exposure, reduced risk, HR
- 0.53 (95% CI 0.30-0.90)
- Propensity-score matched
Original publication
SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network. Diabetes Obes Metab. Published 8 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →